Elena Ivany

Elena Ivany

Auto-generated profile, based on publicly available information

Elena Ivany

University College London Hospitals NHS Foundation Trust London UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2022 in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
EIElena Ivany
Elena Ivany
RLRobyn Lotto
Robyn Lotto
Gregory LipGregory Lip
Gregory Lip
DLDeirdre Lane
Deirdre Lane
Background Stroke prevention in patients with atrial fibrillation (AF) post-intracerebral hemorrhage (ICH) is an area of clinical equipoise. Little is known about the tools and processes that physicians use to make decisions regarding anticoagulation in this high-risk patient population. Objective To explore physicians' decision-making process regarding stroke prevention in patients with AF and a recent history of ICH. Methods Qualitative study, utilizing semistructured interviews and analyzed using Framework analysis. Results Twenty physicians from five European countries (Austria, France, Germany, Spain, United Kingdom) participated. The overarching theme “Managing uncertainty,” addressed the process of making high-risk clinical decisions in the context of little available robust clinical evidence for best practice. Three subthemes were identified under the umbrella theme: (1) “Computing the risks,” captured the challenge of balancing the risks of ischemic stroke with the risk of recurrent ICH in a complex patient population; (2) “Patient factors” highlighted the influence that physician-perceived patients' beliefs and previous experience of stroke had on physicians' decisions; and (3) “Making a decision” explored the process of reaching a final decision regarding initiation of OAC therapy or not. Conclusion Physicians described the process of deciding on stroke prevention in patients with AF post-ICH as “challenging” due to considerable “clinical equipoise.” Key factors that affected decision making were patient comorbidities, functional status, and patient willingness to engage with OAC therapy. Shared decision making was believed to be beneficial, but physicians believed that the ultimate responsibility to decide on stroke prevention lay with the clinician.

8 July 2022 in Stroke
Verified
Journal Article
Open access
PDF file
EIElena Ivany
Elena Ivany
LRLeona A. Ritchie
Leona A. Ritchie
Gregory LipGregory Lip
Gregory Lip
RLRobyn Lotto
Robyn Lotto
DWDavid J. Werring
David J. Werring
DLDeirdre Lane
Deirdre Lane
Background: For patients with atrial fibrillation who survive an intracranial hemorrhage (ICrH), the decision to offer oral anticoagulation (OAC) is challenging and necessitates balancing risk of thromboembolic events with risk of recurrent ICrH. Methods: This systematic review assesses the effectiveness and safety of OAC and/or antiplatelets in patients with atrial fibrillation with nontraumatic ICrH. Bibliographic databases CENTRAL, MEDLINE, EMBASE, and CINAHL were searched. Articles on adults with atrial fibrillation with spontaneous ICrH (intracerebral, subdural, and subarachnoid), receiving antithrombotic therapy for stroke prevention were eligible for inclusion. Results: Twenty articles (50 470 participants) included 2 randomized controlled trials (n=304)‚ 8 observational studies, 8 cohort studies, and 2 studies that meta-analyzed individual-level data from observational studies. OAC therapy was associated with a significant reduction in thromboembolic events (summary relative risk [sRR], 0.51 [95% CI, 0.30–0.86], heterogeneity I 2 =2%; P =0.39, n=5 studies) and all-cause mortality (sRR, 0.52 [95% CI, 0.38–0.71], heterogeneity I 2 =0; P =0.44, n=3 studies). OAC therapy was not associated with an increased risk of recurrent ICrH (sRR, 1.44 [95% CI, 0.38–5.46], heterogeneity I 2 =70%, P =0.02, n=5 studies). Nonvitamin K antagonist OACs were more effective at reducing the risk of thromboembolic events (sRR, 0.65 [95% CI, 0.44–0.97], heterogeneity I 2 =72%, P =0.03, n=3 studies) and were associated with a lower risk of recurrent ICrH (sRR, 0.52 [95% CI, 0.40–0.67], heterogeneity I 2 =0%, P =0.43, n=3 studies) than warfarin. Conclusions: In nontraumatic ICrH survivors with atrial fibrillation, OAC therapy is associated with a reduced risk of thromboembolic events and all-cause mortality without significantly increasing risk of recurrent ICrH. This finding is primarily based on observational data, and further larger randomized controlled trials are needed to corroborate or refute these findings.

28 January 2025 in European Journal of Cardiovascular Nursing
Verified
Journal Article
Open access
EIElena Ivany
Elena Ivany
RLRobyn Lotto
Robyn Lotto
Gregory LipGregory Lip
Gregory Lip
DLDeirdre Lane
Deirdre Lane
Aim: (i) To explore the attitudes of patients with atrial fibrillation (AF) towards oral anti-coagulation (OAC) for stroke prevention post-intracerebral haemorrhage (ICH) and (ii) to explore factors that influence patients’ decision-making process for stroke prevention. Methods and results: Patients with documented diagnosis of AF and history of a non-traumatic ICH, who were eligible for long-term OAC were recruited from eight hospitals in England, using purposive sampling. Data were collected using semi-structured interviews and analysed using Framework analysis. Twelve patients (mean (SD) age 76.2 (6.6) years; 9 men) were recruited. Patients’ main priority was to maintain an acceptable quality of life (QoL), reflected by the main theme ‘Living my life as normal’. When deciding to accept or decline OAC for stroke prevention, patients were influenced by the following: (i) The individual, meaning factors relating to individuals’ personal attitudes towards health and healthcare, (ii) Medical factors, encompassing factors relating to patients’ trust in medical expertise and patients’ information-seeking behaviours, and (iii) Social factors, highlighting the influence of patients’ social support network on patients’ decision-making. Conclusion: Patients’ decision-making for stroke prevention for AF post-ICH was influenced by individual, medical, and social factors. At the heart of patients’, decision-making were concerns with maintaining an acceptable QoL. The study findings help nurses and other healthcare professionals to better understand what matters to patients who are eligible for stroke prevention for AF post-ICH, thus promoting more effective shared decision making.

8 May 2025 in Journal of Nursing Care Quality
Verified
Journal Article
Closed access
JSJoel Mres Stanton
Joel Mres Stanton
CSCarol Msc Stiles
Carol Msc Stiles
PAPaula Ba Anderson
Paula Ba Anderson
RTRachel M Taylor
Rachel M Taylor
CVCecilia Vindrola–Padros
Cecilia Vindrola–Padros
EIElena Ivany
Elena Ivany
Background: There is a lack of evidence-based processes to support nurses in appropriately utilizing one-to-one observations for patients at risk of avoidable harm in acute hospitals. Purpose: The purpose of this systematic review was to identify the decision-making processes surrounding one-to-one observations. Methods: Five databases were searched in July 2020 and July 2024. Papers were included if they discussed decision-making processes for one-to-one observations for acute adult inpatients. Data were extracted to a review database and analyzed thematically. Results: Sixteen publications were included. The decision-making tools described were assessment tools, local processes, and clinical judgement. The most common tool was an institutional decision-making process, which often was a combination of clinical assessment and clinical action guidance. Conclusion: Various tools and processes are used to facilitate decision-making on the use of one-to-one observations but few of the tools are evidence-based.